Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.63 |
| ▸ | KIT | P10721 | 8/20 | 0.59 |
| ▸ | BRAF | P15056 | 5/20 | 0.55 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | CSF1R | P07333 | 3/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5900655 | 0.84 | RXFP1 (0.48) | EGFRKITBRAFRETKDR | |
| SCHEMBL5900585 | 0.83 | ABL1 (0.57) | EGFRKITBRAFRETCSF1R | |
| SCHEMBL5900542 | 0.82 | RXFP1 (0.52) | EGFRKITBRAFKDRCSF1R | |
| SCHEMBL5900863 | 0.81 | RXFP1 (0.53) | EGFRKITBRAFKDRCSF1R | |
| SCHEMBL5900615 | 0.80 | KDR (0.54) | EGFRKITKDRCSF1RABL1 | |
| SCHEMBL21611716 | 0.79 | KIT (0.73) | EGFRKITBRAFRETCSF1R | |
| SCHEMBL5901817 | 0.79 | RXFP1 (0.50) | EGFRKITBRAFKDRCSF1R | |
| SCHEMBL1041884 | 0.78 | RXFP1 (0.48) | EGFRKITBRAFRETKDR | |
| SCHEMBL5900485 | 0.78 | RXFP1 (0.51) | EGFRKITRETKDRCSF1R | |
| SCHEMBL5900523 | 0.78 | KIT (0.69) | EGFRKITBRAFRETABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060128684-A1 | Anthranilic acid amide derivatives and their pharmaceutical use | BOLD GUIDO | 2006-06-15 | — | — | US | claimed |
| CN-1720244-A | Anthranilic acid amide derivatives and their pharmaceutical use | NOVARTIS AG (CH) | 2006-01-11 | — | — | CN | claimed |
| CN-100427483-C | Anthranilic acid amide derivatives and their pharmaceutical use | NOVARTIS AG (CH) | 2008-10-22 | — | — | CN | disclosed |
| US-20060128684-A1 | Anthranilic acid amide derivatives and their pharmaceutical use | BOLD GUIDO | 2006-06-15 | — | — | US | disclosed |
| CN-1720244-A | Anthranilic acid amide derivatives and their pharmaceutical use | NOVARTIS AG (CH) | 2006-01-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128684-A1 | Anthranilic acid amide derivatives and their pharmaceutical use | AADAC, AADAT, NAAA | EGFR 2385/4885KIT 3508/4885BRAF 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.